Kramer Levin secured a complete defense victory for Regeneron Pharmaceuticals in a suit brought by Novartis alleging patent infringement of a biotech patent and seeking $530 million in damages. Novartis argued that Regeneron's manufacture of the drug for its blockbuster products EYLEA and ZALTRAP infringed all claims of Novartis’ patent. We secured favorable claim construction rulings, eliminating each of Novartis’ infringement claims. We also added claims of unclean hands and inequitable conduct and obtained discovery sanctions against Novartis. In September 2019, the court entered judgment of noninfringement on all claims in Regeneron's favor, and Novartis dismissed its action without appeal.